10.5281/zenodo.2040342
https://zenodo.org/records/2040342
oai:zenodo.org:2040342
Harding, Rachel
Rachel
Harding
0000-0002-1134-391X
Structural Genomics Consortium, University of Toronto
Hutchinson, Ashley
Ashley
Hutchinson
Structural Genomics Consortium, University of Toronto
Seitova, Alma
Alma
Seitova
Structural Genomics Consortium, University of Toronto
Arrowsmith, Cheryl
Cheryl
Arrowsmith
Structural Genomics Consortium, University of Toronto
Edwards, Aled
Aled
Edwards
Structural Genomics Consortium, University of Toronto
Large scale expression and purification of full-length huntingtin Q54 with HAP40 from baculoviral expression system production in sf9 insect cells – 2018/08/04
Zenodo
2018
huntingtin
Huntington's disease
HAP40
Protein purification
2018-08-04
10.5281/zenodo.2040341
https://zenodo.org/communities/labscribbles
https://zenodo.org/communities/sgc-opennotebook
https://zenodo.org/communities/openlabnotebooks
Creative Commons Attribution 4.0 International
Project - Huntingtin structure-function open lab notebook.
Rationale - Purified huntingtin samples with and without stabilising binding partners (HAP40) are required for use in structural and functional studies, in particular SAXS experiments.
Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.